Comparative efficacy and acceptability of first-line drugs for the acute treatment of generalized anxiety disorder in adults: A network meta-analysis
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
The guide recommends SSRI and SNRI drugs as first-line treatments for generalized anxiety disorder (GAD). Therefore, we aimed to update the evidence using network meta-analysis by comparing the efficacy and acceptability of first-line drugs. The relevant electronic databases were searched for placebo-controlled and head-to-head trials of 11 drugs used for the acute treatment of adults with GAD from 1980 up to January 1, 2019. Data on demographics, clinical, and treatment information were extracted from each eligible study. The primary outcomes were efficacy (quantified as the change in the total score on the Hamilton Anxiety Scale from baseline) and acceptability (quantified as treatment discontinuations due to any cause). Overall, the data on 41 RCTs were sufficient or appropriate for inclusion. In terms of efficacy, all of the drugs except fluoxetine and vortioxetine were more effective than placebo, with the weighted mean difference of the Hamilton Anxiety Scale score ranging between -3.2 (95% credible interval [CrI] = -4.2 to -2.2) for escitalopram and -1·8 (95% CrI = -3.1 to -0.55) for vilazodone. For acceptability, only vilazodone (OR = 1.7, 95% CrI = 1.1 to 2.7) were worse than placebo, others did not show significant differences from placebo. In head-to-head comparisons, vortioxetine showed better acceptability and tolerability but worse efficacy and response rate. In conclusion, most drugs are more effective than placebo, and there are few significant differences between the active drugs and placebo on acceptability. Overall, duloxetine and escitalopram showed better efficacy while vortioxetine showed better acceptability.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cipriani, A., Furukawa, T. A., Salanti, G., Chaimani, A., Atkinson, L. Z., Ogawa, Y., Leucht, S., Ruhe, H. G., Turner, E. H., Higgins, J. P. T., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)32802-7 · Cited by 3,541
Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies
Higgins, J. P. T., Jackson, D., Barrett, J. K., Lu, G., Ades, A. E., & White, I. R. (2012) · Research Synthesis Methods · doi:10.1002/jrsm.1044 · Cited by 2,098
Katzman, M. A., Bleau, P., Blier, P., Chokka, P., Kjernisted, K., Van Ameringen, M., & the Canadian Anxiety Guidelines Initiative Group on behalf of the Anxiety Disorders Association of Canada/Association Canadienne des troubles anxieux and McGill University (2014) · BMC Psychiatry · doi:10.1186/1471-244x-14-s1-s1 · Cited by 1,090
Craske, M. G., & Stein, M. B. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30381-6 · Cited by 640
Chaimani, A., & Salanti, G. (2012) · Research Synthesis Methods · doi:10.1002/jrsm.57 · Cited by 521
Slee, A., Nazareth, I., Bondaronek, P., Liu, Y., Cheng, Z., & Freemantle, N. (2019) · The Lancet · doi:10.1016/s0140-6736(18)31793-8 · Cited by 372
Gomez, A. F., Barthel, A. L., & Hofmann, S. G. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1472767 · Cited by 125
Functional Recovery in Major Depressive Disorder: Focus on Early Optimized Treatment
Habert, J., Katzman, M. A., Oluboka, O. J., McIntyre, R. S., McIntosh, D., MacQueen, G. M., Khullar, A., Milev, R. V., Kjernisted, K. D., Chokka, P. R., et al. (2016) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.15r01926 · Cited by 84
Research works printed but not linked: 16
- Baldwin, 2011, Efficacy of drug treatments for generalised anxiety disorder: systematic review and meta-analysis, BMJ, 342, d1199, 10.1136/bmj.d1199 · DOI · Paper page
- Bidzan, 2012, Vortioxetine (Lu AA21004) in generalized anxiety disorder: results of an 8-week, multinational, randomized, double-blind, placebo-controlled clinical trial, Eur. Neuropsychopharmacol., 22, 847, 10.1016/j.euroneuro.2012.07.012 · DOI
- Blier, 2017, Effects of levomilnacipran ER on noradrenergic symptoms, anxiety symptoms, and functional impairment in adults with major depressive disorder: post hoc analysis of 5 clinical trials, J. Affect. Disord., 210, 273, 10.1016/j.jad.2016.11.011 · DOI
- Butler, 1993, Predicting outcome after treatment for generalised anxiety disorder, Behav. Res. Ther., 31, 211, 10.1016/0005-7967(93)90075-6 · DOI
- Canadian Psychiatric Association, 2006, Clinical practice guidelines. Management of anxiety disorders, Can. J. Psychiatr., 51, 9S
- Christensen, 2017, Efficacy of vortioxetine in working patients with generalized anxiety disorder, CNS Spectr., 1
- He, 2018, Efficacy and tolerability of different doses of three new antidepressants for treating major depressive disorder: a PRISMA-compliant meta-analysis, J. Psychiatr. Res., 96, 247, 10.1016/j.jpsychires.2017.10.018 · DOI
- Kudlow, 2012, Predicting treatment response in major depressive disorder: the impact of early symptomatic improvement, Can. J. Psychiatr., 57, 782, 10.1177/070674371205701211 · DOI · Paper page
- Liebowitz, 2017, Vortioxetine versus placebo in major depressive disorder comorbid with social anxiety disorder, Depress. Anxiety, 34, 1164, 10.1002/da.22702 · DOI · Paper page
- Mahableshwarkar, 2014, A randomised, double-blind, placebo-controlled, duloxetine-referenced study of the efficacy and tolerability of vortioxetine in the acute treatment of adults with generalised anxiety disorder, Int. J. Clin. Pract., 68, 49, 10.1111/ijcp.12328 · DOI · Paper page
- Mahableshwarkar, 2014, A randomized, double-blind, fixed-dose study comparing the efficacy and tolerability of vortioxetine 2.5 and 10 mg in acute treatment of adults with generalized anxiety disorder, Hum. Psychopharmacol., 29, 64, 10.1002/hup.2371 · DOI · Paper page
- Rothschild, 2012, Vortioxetine (Lu AA21004) 5 mg in generalized anxiety disorder: results of an 8-week randomized, double-blind, placebo-controlled clinical trial in the United States, Eur. Neuropsychopharmacol., 22, 858, 10.1016/j.euroneuro.2012.07.011 · DOI
- Sandelin, 2013, Treatment patterns and costs in patients with generalised anxiety disorder: one-year retrospective analysis of data from national registers in Sweden, Eur. Psychiatry, 28, 125, 10.1016/j.eurpsy.2012.02.003 · DOI
- Shah, 2018, An open-label, flexible dose adaptive study evaluating the efficacy of vortioxetine in subjects with panic disorder, Ann. Gen. Psychiatr., 17, 19, 10.1186/s12991-018-0190-6 · DOI · Paper page
- Yee, 2018, Vortioxetine treatment for anxiety disorder: a meta-analysis study, Curr. Drug Targets, 19, 1412, 10.2174/1389450118666171117131151 · DOI
- Zareifopoulos, 2017, Efficacy and tolerability of vilazodone for the acute treatment of generalized anxiety disorder: a meta-analysis, Asian. J. Psychiatr., 26, 115, 10.1016/j.ajp.2017.01.016 · DOI
Cited by
Leichsenring, F., Steinert, C., Rabung, S., & Ioannidis, J. P. A. (2022) · World Psychiatry · doi:10.1002/wps.20941 · Cited by 485
Pharmacotherapy of Anxiety Disorders: Current and Emerging Treatment Options
Garakani, A., Murrough, J. W., Freire, R. C., Thom, R. P., Larkin, K., Buono, F. D., & Iosifescu, D. V. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.595584 · Cited by 440
“A recent meta-analysis reported that most SSRIs and SNRIs are more efficacious than placebo in GAD, with escitalopram and duloxetine potentially having the largest effect sizes (17).”
Pharmacotherapy for Anxiety Disorders: From First-Line Options to Treatment Resistance
Melaragno, A. J. (2021) · Focus · doi:10.1176/appi.focus.20200048 · Cited by 50
Pharmacotherapy for Anxiety Disorders.
O’Leary, K. B., & Khan, J. S. (2024) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2024.04.012 · Cited by 22
Antidepressants versus placebo for generalised anxiety disorder (GAD)
Kopcalic, K., Arcaro, J., Pinto, A., Ali, S., Barbui, C., Curatoli, C., Martin, J., & Guaiana, G. (2025) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012942.pub2 · Cited by 16
Metadata
- Authors
- He, H., Xiang, Y., Gao, F., Bai, L., Gao, F., Fan, Y., Lyu, J., & Ma, X.
- Venue
- Journal of Psychiatric Research
- Publisher
- Elsevier BV
- Published
- 2019-11
- Volume
- 118
- Pages
- 21-30
- ISSN
- 0022-3956 (ISSN-L)
- OpenAlex
- W2967119862
- Cited by
- 39
- References
- 8
- FWCI
- 5.04
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- Funders
- National Natural Science Foundation of China
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Comparative efficacy and acceptability of first-line drugs for the acute treatment of generalized anxiety disorder in adults: A network meta-analysis. https://app.cochat.ai/papers/10.1016/j.jpsychires.2019.08.009
- The paper
- He, H., Xiang, Y., Gao, F., Bai, L., Gao, F., Fan, Y., Lyu, J., & Ma, X. (2019). Comparative efficacy and acceptability of first-line drugs for the acute treatment of generalized anxiety disorder in adults: A network meta-analysis. Journal of Psychiatric Research. https://doi.org/10.1016/j.jpsychires.2019.08.009
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.